, novel coronavirus pneumonia, announced novel coronavirus pneumonia in August 23rd. The food and Drug Administration announced that it urgently authorized the use of plasma therapy for new crown pneumonia patients, and said its “known and potential benefits outweigh the known and potential risks”. U.S. President trump said plasma therapy was a “historic breakthrough” that would save countless lives. The U.S. Food and drug administration says more than 70000 patients have been treated with plasma, which is made from recovered blood from patients infected with new coronavirus. < p > < p > according to the US consumer news and business channel, although tens of thousands of patients in the United States have made it part of clinical trials, the latest treatment guidelines of the National Institutes of health show that plasma therapy currently lacks “sufficient data” support. The U.S. Food and drug administration is under Trump’s pressure to authorize plasma treatment for patients with the new crown, the US Capitol Hill newspaper reported. According to the report, trump has been seeking new progress in the fight against the epidemic, which he touted as a “historic breakthrough” in a white house media briefing. < p > < p > previously, the FDA has suspended the approval of plasma therapy as a new crown treatment, because several senior health officials, including Dr. fudge, consultant of new coronavirus in the White House, and Dr. Francis Collins, director of the National Institutes of health, believed that plasma therapy lacked important randomized controlled trial data, and the existing experimental data were not enough to support this treatment scheme. “The problem is that we don’t have enough data to really understand the effectiveness of plasma therapy,” says Jonathan Reiner, a professor of medicine at George Washington University “It’s hoped that when a treatment does work, we have enough confidence in it, and we can produce uncontroversial evidence, we can re authorize it,” said Dr. Mira ortigos, an infectious disease expert at New York University “We are now facing the lives of patients,” she stressed. As with blood, the supply of therapeutic plasma is limited and must come from donors. Many experts said that even if this method is effective, the current use of plasma therapy also has limitations. Janet Woodcock, director of the FDA’s Center for drug evaluation and research, said the number of plasma donors is limited now, but there is a great deal of enthusiasm for this treatment that has exceeded expectations. < p > < p > Kaplan also pointed out that with the urgent authorization of the plasma treatment program, doctors will treat patients without data tracking, and it will be difficult to determine which donors donate the most effective plasma and which types of patients are suitable for receiving the program. It’s also a distraction to the treatment itself. Dr. William Schaffner, an infectious disease expert at Vanderbilt University, said more evidence was needed for plasma therapy. Now scientists are working novel coronavirus pneumonia to develop hundreds of drugs. Trump has been providing “various treatment recommendations”. These suggestions are often not supported scientifically or even very dangerous.